| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13D · 4 securities · may seek to influence control | ||||||
|
Tempest Therapeutics, Inc.
13D/A
TPST · 87978U108
|
1.1% |
4/2/2026
Event 3/30/2026
|
||||
| Versant Venture Capital VI, L.P. | 0.1% | |||||
| Versant Ventures VI GP, L.P. | 0.1% | |||||
| Versant Ventures VI GP-GP, LLC | 0.1% | |||||
| Versant Vantage II, L.P. | 1.1% | |||||
| Versant Vantage II GP, L.P. | 1.1% | |||||
| Versant Vantage II GP-GP, LLC | 1.1% | |||||
| Versant Venture Capital IV, L.P. | 0.6% | |||||
| Versant Side Fund IV, L.P. | 0% | |||||
| Versant Ventures IV, LLC | 0.6% | |||||
|
Monte Rosa Therapeutics, Inc.
13D/A
GLUE · 61225M102
|
3.4% |
1/9/2026
Event 1/7/2026
|
||||
| Versant Venture Capital VI, L.P. | 3.4% | |||||
| Versant Ventures VI GP, L.P. | 3.4% | |||||
| Versant Ventures VI GP-GP, LLC | 3.4% | |||||
| Versant Vantage I, L.P. | 1.6% | |||||
| Versant Vantage I GP, L.P. | 1.6% | |||||
| Versant Vantage I GP-GP, LLC | 1.6% | |||||
|
LENZ Therapeutics, Inc.
13D/A
LENZ · 52635N103
|
3.4% |
11/10/2025
Event 11/5/2025
|
||||
| Versant Venture Capital VI, L.P. | 3.4% | |||||
| Versant Ventures VI GP, L.P. | 3.4% | |||||
| Versant Ventures VI GP-GP, LLC | 3.4% | |||||
| Versant Vantage II, L.P. | 2.7% | |||||
| Versant Vantage II GP, L.P. | 2.7% | |||||
| Versant Vantage II GP-GP, LLC | 2.7% | |||||
| Versant Venture Capital VII, L.P. | 2.7% | |||||
| Versant Ventures VII GP, L.P. | 2.7% | |||||
| Versant Ventures VII GP-GP, LLC | 2.7% | |||||
|
LAVA Therapeutics N.V.
13D/A
LVTX · N51517105
|
0% |
9/23/2025
Event 9/19/2025
|
||||
| Versant Venture Capital VI, L.P. | 0% | |||||
| Versant Ventures VI GP, L.P. | 0% | |||||
| Versant Ventures VI GP-GP, LLC | 0% | |||||
| Versant Vantage I, L.P. | 0% | |||||
| Versant Vantage I GP, L.P. | 0% | |||||
| Versant Vantage I GP-GP, LLC | 0% | |||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.